NEW YORK (GenomeWeb News) – Molecular diagnostics firm Evogen said this week that it has raised $3 million in a series B round of venture capital funding.
The round was led by New York-based venture capital firm L Capital Partners.
Evogen, which formerly was named Sceptor Industries, is developing a PCR-based diagnostics instrument called the EvoCycler HD12. The Kansas City, Mo.-based firm said the instrument costs 50 percent less than instruments with similar capabilities and is small enough to fit on a desktop.
After the anthrax scare of 2001, the US Postal Service had installed Sceptor’s SpinCon aerosol collection device in every mail-sorting center nationwide, according to Evogen. The firm said that the firm now can combine Sceptor’s aerosol collection technology with molecular diagnostics for use in a variety of applications.
“Our portfolio of technologies and applications allow us to further expand beyond the biodefense market into commercial markets, including clinical diagnostics, environmental testing, and research,” Evogen President and CEO Sean Reineke said in a statement.